Gish's cardiopulmonary products address a $500,000,000 annual
market worldwide.gishbiomedical.runonideas.

convictions permit

The Los Angeles Times in its January 31, 2005 Health section featured a
front page, multicolumn article focusing on the growing trend towards
transfusion-free cardiothoracic surgery, not just for Jehovah's Witnesses , but
for elective surgeries as well.

blood undertaken

com

Robert Winslow, a world-renowned authority in the field of oxygen
transport, founded Sangart in 1998.

substitutes immobilization

Pope John Paul II was ill for two months with
symptoms similar to mononucleosis or hepatitis, contracted from transfusions
he received after a 1981 assassination attempt. Times color
photographs.5 billion annual market.

Investor contact:
Aurelius Consulting Group:
Dave Gentry, 407/644-4256
dave@aurcg.

Sangart Initiates Phase II Clinical Trial for Hemospan(R)

Winslow's group on the effective
action of oxygen transport agents have been patented and published in numerous
scientific articles.

permit jehovah

WILMINGTON , Mass.
The Vision (TM) CBP Equipment is manufactured and sold by Gish Biomedical,
Inc.sabm . Preclinical
and clinical studies indicate that Hemospan(R) is free of harmful vasoactivity
and provides targeted oxygen delivery to tissues at risk of oxygen
deprivation.
Dr. In the two decades prior to founding
Sangart, Dr.

transfusions wondered

This study, involving 40 patients, will be conducted at the Johns Hopkins
University School of Medicine in Baltimore.

isabi immobilization

The counterintuitive discoveries by Dr.

accept immobilization

Douglas Whittaker, President of Gish Biomedical commented, "We are
gratified to have seen our equipment in use in one the L.noblood. Additionally,
CardioTech has partnered with Implant Sciences and CorNova to develop a drug-
eluting stent that addresses a $1 billion international market .com
http://www.
Sangart's corporate headquarters are in San Diego, California.

permit convictions

, CardioTech
International, Inc. From this experience, Sangart's lead product,
Hemospan(R), was designed using unique polyethylene glycol conjugation to
create a hemoglobin-based product that is intended to serve as an alternative
to donated blood. To learn
more about Sangart, please visit the company's website at http://www.

undergoing regard

com.

isabi blood

The Vision CBP includes
oxygenators, reservoirs, filters and Cardioplegia units , which are now
considered mainstream components in transfusion-free surgeries specifically
targeted to Jehovah's Witnesses who adhere to a biblical admonition against
receiving blood.org; Gish Biomedical website:
http://www. These breakthroughs laid the groundwork for Sangart's
business concept of developing cost-effective oxygen carriers that can be used
in lieu of transfused red blood cells during episodes of temporary blood loss,
such as surgery or trauma.sangart.

elective permit

You can learn more about transfusion-free medicine at the
following websites: Jehovah's Witnesses health website:
http: //www.

minimize donors

Current revenue sources include
patented polyurethanes, medical devices, contract manufacturing , and
disposables used during cardiopulmonary bypass procedures.

avoidance blood

We are pleased to provide information concerning this matter
as a public service."
Sangart's approach to the development of oxygen transport agents employs
novel technology, the result of more than a decade of peer-reviewed research
into the mechanism of oxygen transport by cell-free hemoglobin.

transfusion undertaken

SAN DIEGO, Sangart , Inc.

undertaken ispot

com; and the Society for the Advancement of Blood
Management: http://www., a biopharmaceutical
company developing oxygen transport agents, announced today the initiation of
a Phase II clinical trial involving Hemospan(R) (MP4), a hemoglobin-based
oxygen carrier designed to serve as an alternative for blood transfusions. Winslow, M. It will build on the favorable safety database already
established in Europe and will be the first trial of MP4 as a replacement for
surgical blood loss.

convictions avoidance

Gish Cardiopulmonary Bypass Equipment Used in Pioneering Transfusion-free Surgery

, a wholly owned subsidiary of CardioTech . maintains operations in Wilmington,
Massachusetts; Plymouth, Minnesota and Rancho Santa Margarita , California.

accept transfusion

About Sangart
Sangart is a privately held biopharmaceutical company focused on the
research, development and commercialization of medical products designed for
use as alternatives to blood transfusions. Winslow and his colleagues studied and defined mechanisms of
oxygen transport by cell-free hemoglobin solutions, funded by competitive
grants from the National Institutes of Health and the Department of Defense.

undergoing ispot

For further
information you are encouraged to review CardioTech's filings with the
Securities and Exchange Commission.

immobilization ispot

(Amex: CTE) today announced that the Vision (TM)
Cardiopulmonary Bypass (CPB) equipment is being used at Fountain Valley
Regional Hospital and Medical Center in Orange County, which has one of the
nation's oldest transfusion-free surgery programs.org. CardioTech is
currently conducting human clinical trials with a synthetic coronary artery
bypass graft that addresses a $1.D.

avoidance elective

CardioTech believes that this release contains forward-looking statements
that are subject to risks and uncertainties.

transfusions substitutes

, Chairman and Chief Executive Officer of Sangart,
commented, "This trial marks the initiation of Sangart's US clinical
development program.
The key breakthroughs in the development of Hemospan(R) were the
understanding of the mechanisms of vasoconstriction and the development of
simplified production methods that are designed to make the final product
commercially viable.

elective avoidance

Such statements are based on
management 's current expectations and are subject to facts that could cause
results to differ materially from the forward-looking statements.
Robert M.

convictions coordinate

A.

About CardioTech
CardioTech International , Inc.

carefully bloodless

CardioTech focuses on developing, manufacturing and marketing devices to
surgically treat cardiovascular disease.